Literature DB >> 21612783

Developing counter current chromatography to meet the needs of pharmaceutical discovery.

Neil Sumner1.   

Abstract

Experiments have been carried out to evaluate Counter Current Chromatography (CCC) as an alternative purification technique to preparative Reverse Phase High Performance Liquid Chromatography (RP-HPLC) for small molecule pharmaceuticals. The major drawback of CCC is the extensive time required in selecting the solvents to perform the separation. This is equivalent to choosing both the stationary phase and the mobile phase at the same time. In RP-HPLC it is a simple matter of deciding on the gradient, most samples can be purified on a C18 column with a water:acetonitrile gradient. The majority of the initial work was based on a standard test set of commercially available compounds, developed within our group to evaluate the performance of the HPLC apparatus and the column prior to the start of work each day. The work carried out on CCC has shown that the technique offers similar capabilities and can be carried out using similar protocols to RP-HPLC. CCC also has some advantages over RP-HPLC and can be regarded as a valuable addition to the chromatography toolbox.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612783     DOI: 10.1016/j.chroma.2011.05.001

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  2 in total

1.  The Generally Useful Estimate of Solvent Systems (GUESS) method enables the rapid purification of methylpyridoxine regioisomers by countercurrent chromatography.

Authors:  Yang Liu; J Brent Friesen; Larry L Klein; James B McAlpine; David C Lankin; Guido F Pauli; Shao-Nong Chen
Journal:  J Chromatogr A       Date:  2015-11-17       Impact factor: 4.759

2.  Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin.

Authors:  Yiwen Huang; Xiaoqing He; Taizhi Wu; Fuli Zhang
Journal:  Molecules       Date:  2016-08-09       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.